Systemic functional expression of N-acetyltransferase polymorphism in the F344 Nat2 congenic rat.
Rat lines congenic for the rat N-acetyltransferase 2 [(RAT)Nat2] gene were constructed and characterized. F344 (homozygous Nat2 rapid) males were mated to Wistar Kyoto (homozygous Nat2 slow) females to produce heterozygous F1. F1 females were then backcrossed to F344 males. Heterozygous acetylator female progeny from this and each successive backcross were identified by rat Nat2 genotyping and mated with F344 rapid acetylator males. After 10 generations of backcross mating, heterozygous acetylator brother/sister progeny were mated to produce the homozygous rapid and slow acetylator Nat2 congenic rat lines. p-Aminobenzoic acid (selective for rat NAT2) and 4-aminobiphenyl N-acetyltransferase activities were expressed in all tissues examined (liver, lung, esophagus, stomach, small intestine, colon, pancreas, kidney, skin, leukocytes, and urinary bladder in male and female rats and in breast of female and prostate of male rats). NAT2 expression in rat extrahepatic tissues was much higher than that in liver. In each tissue, activities were Nat2-genotype-dependent, with the highest levels in homozygous rapid acetylators, intermediate levels in heterozygous acetylators, and lowest in homozygous slow acetylators. Sulfamethazine (selective for rat NAT1) N-acetyltransferase activities were observed in all tissues examined in both male and female rats except for breast (females), bladder, and leukocytes. In each tissue, the activity was Nat2 genotype-independent, with similar levels in homozygous rapid, heterozygous, and homozygous slow acetylators. These congenic rat lines are useful for investigating the role of NAT2 genetic polymorphisms in susceptibility to cancers related to arylamine carcinogen exposures.
Hein
David W
DW
Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40292, USA. d.hein@louisville.edu
Bendaly
Jean
J
Neale
Jason R
JR
Doll
Mark A
MA
D010129:4-Aminobenzoic Acid / Q000378:metabolism; D000611:Aminobiphenyl Compounds / Q000378:metabolism; D000818:Animals; D020296:Animals, Congenic; D001191:Arylamine N-Acetyltransferase / Q000235:genetics / Q000378:metabolism*; D005260:Female; D015971:Gene Expression Regulation, Enzymologic; D006579:Heterozygote; D006720:Homozygote; D007527:Isoenzymes / Q000235:genetics / Q000378:metabolism; D008297:Male; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D051381:Rats; D011916:Rats, Inbred F344; D011921:Rats, Inbred WKY; D012727:Sex Characteristics; D013418:Sulfamethazine / Q000378:metabolism
D000611:Aminobiphenyl Compounds; D007527:Isoenzymes; C006757:4-biphenylamine; D013418:Sulfamethazine; D001191:Arylamine N-Acetyltransferase; C089384:N-acetyltransferase 1; C541077:NAT2 protein, rat; D010129:4-Aminobenzoic Acid
Toxicol Appl Pharmacol. 1999 May 1;156(3):187-94
10222311
Drug Metab Dispos. 1991 Sep-Oct;19(5):933-7
1686239
Arch Toxicol. 1992;66(2):112-7
1605725
J Pharmacol Exp Ther. 2006 Jan;316(1):289-94
16192314
Carcinogenesis. 1993 Aug;14(8):1633-8
8353847
Cancer Epidemiol Biomarkers Prev. 2000 May;9(5):529-32
10815700
Toxicol Appl Pharmacol. 1997 Nov;147(1):56-62
9356307
Drug Metab Dispos. 2007 Jul;35(7):1064-70
17403913
Toxicol Appl Pharmacol. 1994 Jan;124(1):16-24
8291057
Pharmacogenet Genomics. 2006 Jul;16(7):515-25
16788383
Pharmacogenetics. 2003 Jul;13(7):399-407
12835615
Drug Metab Dispos. 2007 May;35(5):721-7
17287389
J Pharmacol Exp Ther. 1991 Nov;259(2):699-704
1941618
Drug Metab Dispos. 1993 Nov-Dec;21(6):1057-63
7905384
Biochem Pharmacol. 1973 Jul 1;22(13):1581-8
4729805
Drug Metab Dispos. 2008 Dec;36(12):2445-51
18799802
Drug Metab Rev. 2005;37(3):511-64
16257833
Exp Neurol. 2004 May;187(1):199-202
15081601
Drug Metab Dispos. 2006 Oct;34(10):1697-702
16815960
Cancer Lett. 2000 Feb 28;149(1-2):53-60
10737708
Gene. 1994 Mar 25;140(2):247-9
8144033
J Pharmacol Exp Ther. 1999 Jul;290(1):182-7
10381774
Pharmacogenetics. 1995 Aug;5(4):247-51
8528272
Jpn J Cancer Res. 1985 Jul;76(7):570-6
3928552
Mol Pharmacol. 1991 Aug;40(2):218-27
1875909
Mol Carcinog. 2006 Apr;45(4):230-8
16482518
Carcinogenesis. 2003 Apr;24(4):719-25
12727801
Mutat Res. 2002 Sep 30;506-507:65-77
12351146
Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):15-26
18187392
Arch Biochem Biophys. 2007 Aug 15;464(2):169-75
17601487
Pharmacogenetics. 1997 Apr;7(2):121-30
9170149
Oncogene. 2006 Mar 13;25(11):1649-58
16550165
Rapid Commun Mass Spectrom. 2003;17(18):2125-32
12955743
Toxicol Sci. 2007 Oct;99(2):413-21
17567587
Mol Pharmacol. 2003 Jul;64(1):170-9
12815173
Pharmacogenetics. 1994 Apr;4(2):91-100
7915937
Food Chem Toxicol. 1999 Feb-Mar;37(2-3):125-34
10227736
Biochem Pharmacol. 1996 Nov 22;52(10):1613-20
8937477
J Pharmacol Exp Ther. 1991 Jul 1;258(1):232-6
2072298
J Pharmacol Exp Ther. 2006 Oct;319(1):369-75
16829624
Drug Metab Dispos. 1993 Sep-Oct;21(5):965-6
7902264
Nucleic Acids Res. 1989 May 11;17(9):3589
2726493
Pharmacogenetics. 1991 Oct;1(1):50-7
1844823
Drug Metab Dispos. 1995 Feb;23(2):295-7
7736928
Biochem J. 1973 Mar;132(3):519-26
4724587
Environ Mol Mutagen. 2002;39(2-3):184-92
11921188
J Pharmacol Exp Ther. 2006 Nov;319(2):724-8
16857729
Drug Metab Dispos. 2007 Sep;35(9):1649-56
17591675
Biomarkers. 2008 Feb;13(1):106-18
17896208